Incyte announces positive interim data from Phase 2 trial of Pemigatinib
Incyte announced updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib, its selective fibroblast growth factor receptor inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate of 40%, the primary endpoint, and a median progression free survival of 9.2 months, a key secondary endpoint. Pemigatinib was well-tolerated. The most common treatment-emergent adverse events were hyperphosphatemia, alopecia, diarrhea, decreased appetite and fatigue. Five patients had TEAEs with a fatal outcome, none of which were related to study treatment.